Tenax Therapeutics Inc


Prices are adjusted according to historical splits.

Tenax Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$7.73 million
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Tenax Therapeutics Inc had its IPO on 1997-01-02 under the ticker symbol TENX.

The company operates in the Healthcare sector and Biotechnology industry. Tenax Therapeutics Inc has a staff strength of 7 employees.

Stock update

Shares of Tenax Therapeutics Inc opened at $0.35 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $0.32 - $0.36, and closed at $0.36.

This is a -1.39% slip from the previous day's closing price.

A total volume of 1,170,000 shares were traded at the close of the day’s session.

In the last one week, shares of Tenax Therapeutics Inc have increased by +5.97%.

Tenax Therapeutics Inc's Key Ratios

Tenax Therapeutics Inc has a market cap of $7.73 million, indicating a price to book ratio of 1.5883 and a price to sales ratio of 0.

In the last 12-months Tenax Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-9868784. The EBITDA ratio measures Tenax Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Tenax Therapeutics Inc’s operating margin was 0% while its return on assets stood at -64.93% with a return of equity of -122.55%.

In Q1, Tenax Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Tenax Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-5.46 per share while it has a forward price to earnings multiple of 0.5404 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tenax Therapeutics Inc’s profitability.

Tenax Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.2316. Its price to sales ratio in the trailing 12-months stood at 0.

Tenax Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$15.27 million
Total Liabilities
Operating Cash Flow
Capital Expenditure
Dividend Payout Ratio

Tenax Therapeutics Inc ended 2023 with $15.27 million in total assets and $0 in total liabilities. Its intangible assets were valued at $15.27 million while shareholder equity stood at $14.28 million.

Tenax Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $983861.00 in other current liabilities, 2178.00 in common stock, $-290948840.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.41 million and cash and short-term investments were $14.41 million. The company’s total short-term debt was $513,906 while long-term debt stood at $0.

Tenax Therapeutics Inc’s total current assets stands at $15.26 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $172034.00 and inventory worth $0.

In 2023, Tenax Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $1241.

Comparatively, Tenax Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Tenax Therapeutics Inc stock is currently trading at $0.36 per share. It touched a 52-week high of $13.8 and a 52-week low of $13.8. Analysts tracking the stock have a 12-month average target price of $5.5.

Its 50-day moving average was $0.36 and 200-day moving average was $2.04 The short ratio stood at 0.28 indicating a short percent outstanding of 0%.

Around 248% of the company’s stock are held by insiders while 189% are held by institutions.

Frequently Asked Questions About Tenax Therapeutics Inc

The stock symbol (also called stock or share ticker) of Tenax Therapeutics Inc is TENX

The IPO of Tenax Therapeutics Inc took place on 1997-01-02

Similar Industry Stocks (Biotechnology)

Last Price
Kaya Limited (KAYA)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.


ONE Copley Parkway, Morrisville, NC, United States, 27560